Compare Johnson & Johnson (JNJ) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Snap Inc — how do they compare? Johnson & Johnson trades at $255.8 (market cap $618.09B), while Snap Inc trades at $5.89 (market cap $9.83B). The key difference: Johnson & Johnson is far larger — about 62.9× Snap Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Snap Inc for 68 Days on average.
| JNJ | SNAP | |
|---|---|---|
Market Cap | $618.09B | $9.83B |
Volume | 6,050,983 | 28,532,342 |
Sector | Health | Media |
52-Week High | $278.43 | $9.09 |
52-Week Low | $186.00 | $3.93 |
Typical Hold Time | 129 Days | 68 Days |
Enterprise Value | $646.37B | $11.39B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
Snap Inc. (SNAP) trades at $5.81, up 0.17% with a bullish technical signal. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M vs -$1.4B in 2022). Recent news highlights AI integration in SPECS glasses with NVIDIA and Salesforce partnerships. Analyst consensus is mixed with 38% buy ratings and $7.78 price target, representing 34% upside potential.
Snap presents a turnaround story with improving financials but remains unprofitable. The stock offers potential upside from AI initiatives and revenue growth, balanced by competitive pressures and regulatory risks. Current valuation at 1.55 P/S appears reasonable for the growth trajectory, though profitability remains the key hurdle for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
